Antibody drug developer spun out of Miyazaki and Fujita universities, focused on human and pet monoclonal antibodies.
| Date | Round | Amount |
|---|---|---|
| Dec 2024 | Funding round MabGenesis raised 470M yen in its latest round to accelerate antibody drug development for pets, with participation from Axil Capital and regional funds. | $3.1M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.